© Copyright khedmeh Wall
The cat allergy is arguably the saddest development for cat lovers. The moment you come in contact with the cat, you start to sneeze, experience runny nose, itchy eyes, skin rashes, and even have asthma problems.
Cat allergies affect one in ten people, which is a significant number. Cat allergies affect as much as 30% of the population in some places.
Many people who claim to be cat slaves insist on owning cats while suffering from allergies. Some people, on the other hand, are forced to euthanize their cats because they or members of their family suffer from severe allergies. It hurts in both cases.
Contrary to popular belief, cat fur is not the problem. The primary allergen is a protein called Fel d 1 that is released by the sebaceous and salivary glands of cats. This protein, which cats lick all over their bodies, adheres to carpets, curtains, bed sheets, people's hair, and clothing, and is released into the air through dander and hair. Even after a thorough cleanup, felt d 1 is challenging to get rid of due of its extreme stickiness. Most people can benefit from finding an anti-allergic treatment that targets Fel d 1.
Through immune control mechanisms, allergen-specific iimmunotherapy (AIT), a treatment that promotes tolerance, alters the course of allergic disorders.
Recently, researchers from the Luxembourg Institute of Health explained in an article published in the journal Allergy under the title "Comprehensive mapping of immune tolerance yields a regulatory TNF receptor 2 signature in a murine model of successful Fel d 1-specific immunotherapy using high-dose" that high-dose specific adjuvant molecules CpG oligonucleotides can modify the immune system's allergic response to the major cat allergen Fel d 1, thereby promoting human tolerance.
The ability of humans to endure the highest CpG dose in endotoxin-free conditions was assessed after researchers built a BALB/c OlaHsd mice efficacy model allergic to Fel d 1 in order to study the clinical effect of high-dose CpG adjuvant AIT. It was discovered that the allergic mice treated with AIT showed lower IgE levels and higher IgA and IgG (anti-inflammatory effects), and the lung function and respiratory tract inflammation were obviously improved. This was done by detecting the Fel d 1 specific antibodies in the serum of the mice.
The levels of pro-allergic cytokines in mice treated with AIT were found to be lower than those in untreated allergic mice when the researchers looked further into the cytokines in mouse bronchoalveolar lavage fluid (BALF). This demonstrates how AIT can lessen bronchial hyperresponsiveness and airway inflammation in a preclinical setting.
The researchers also observed that a significant number of immune cells involved in allergy regulation and tolerance, such as regulatory T cells (T-regs), regulatory B cells (B-regs), natural killer cells (NKs), plasmacytoid dendritic cells (pDC), and regulatory T cells (T-regs), expressed high levels of tumor necrosis factor (TNF-), tumor necrosis factor receptor (TNFR-2), and act as a "brake" on the immune system.
The researchers also discovered that AIT activates a novel Treg dubbed biTreg, which can balance effector cells' responses to antigens. This underlines the anti-allergic impact of AIT and the reversibility of allergic features.
In order to translate these findings into clinical practice, scientists have created a subcutaneous (sc) injection medication delivery technique that is more efficient than conventional intraperitoneal (IP) injection at reducing the amount of airway eosinophils and inhibiting the Th2 immune response.
The researchers created a medically acceptable mode of delivery and optimized the ATI specific therapy for cat allergy based on the highest CpG dose that humans could take, setting the groundwork for the creation of novel allergic immunotherapy.
In addition to AIT, researchers are still developing alternative strategies.
1. Vaccinate cats to stop them from developing fel d 1.
2. Through the cat food, the antibodies that neutralize allergens are immediately injected into the cat's body.
Exosomes have emerged as potential treatments for central nervous system (CNS) disorders, thanks to cutting-edge research. This development is particularly significant in a field where exosome effectiveness has become paramount.
In the last decade, researchers have revealed the crucial role of extracellular vesicles (EVs), such as exosomes, in facilitating both short-range and long-range communication among brain cells and beyond. These vesicles serve as carriers for bioactive molecules, encompassing proteins, nucleic acids, lipids, and even functional miRNAs.
Exosome diagnostics are emerging as valuable tools for identifying and characterizing CNS diseases. Their role in intercellular communication and ability to carry distinctive genetic material can thus be seen as biomarkers for identifying and treating a variety of disorders.
Some exosome surface markers exhibit disease specificity, making them potential biomarkers for disease diagnosis. Diseases involved in the discovery and research of exosomes as diagnostic biomarkers include but are not limited to:
* Tumor Diagnosis-Applied Exosomes
* Pregnancy Disorders Diagnosis-Applied Exosomes
* Cardiovascular Diseases Diagnosis-Applied Exosomes
Exosomes in the brain can be released by sources such as bone marrow (BM)-derived stem cells, neural stem cells (NSCs), and mesenchymal stem cells (MSCs), affecting numerous brain disorders such as stroke, Alzheimer's disease (AD), Parkinson's disease (PD), among others.
Beyond diagnostics, recent research has unveiled the potential of exosomes in the treatment of CNS diseases, offering new hope for patients with conditions like Alzheimer's disease, Parkinson's disease, and traumatic brain injury (TBI). One significant breakthrough is the discovery that exosomes derived from stem cells have neuroprotective properties, promoting neurogenesis and modulating inflammation in the CNS.
Exosome in Alzheimer's Disease
Exosomes produced by mesenchymal stem cells (MSCs) have been discovered to have neuroprotective qualities. In clinical settings, these exosomes can improve cognitive performance and slow the buildup of amyloid- plaques, a hallmark pathology of Alzheimer's disease. According to this study, exosome-based therapeutics might be a viable option for halting or even reversing the progression of Alzheimer's disease.
Exosome in Parkinson
By delivering therapeutic compounds and encouraging the survival of dopaminergic neurons, exosomes have proven they have the ability to reduce the symptoms of Parkinson's disease. Exosomes from various sources, such as MSCs and neural stem cells, have been shown to boost neuroprotective effects and reduce neuroinflammation in Parkinson's disease models, according to recent research.
Exosome in Traumatic Brain Injury
Long-term neurological impairments are frequently a result of traumatic brain injuries (TBI). Exosomes made from MSCs have demonstrated the capacity to reduce neuroinflammation and advance tissue regeneration in TBI models. These results imply that exosome-based therapeutic approaches may present fresh opportunities for the management and rehabilitation of TBI.
In summary, exosomes are emerging as a promising avenue for both diagnosis and treatment in the realm of CNS diseases. Their potential to serve as diagnostic biomarkers and therapeutic agents holds significant promise for improving the lives of patients with various neurological conditions.